Reduced CYP2D6 function is associated with gefitinib-induced rash in patients with non-small cell lung cancer

Abstract

The frequency of rash was significantly higher in patients with reduced CYP2D6 activity who treated with gefitinib compared to patients with functional CYP2D6. CYP2D6 phenotypes are a risk factor for the development of rash in response to gefitinib therapy.